Frontal affinity chromatography with MS detection (FAC-MS) in drug discovery

被引:64
|
作者
Slon-Usakiewicz, JJ [1 ]
Ng, W [1 ]
Dai, JR [1 ]
Pasternak, A [1 ]
Redden, PR [1 ]
机构
[1] Lead Discovery & Optimizat Div, Toronto, ON M9W 7H4, Canada
关键词
D O I
10.1016/S1359-6446(04)03360-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The emergence of a relatively new technique resulting from a combination of frontal affinity chromatography coupled with MS detection (FAC-MS) has extended the capabilities of MS in drug discovery and development. Its application in a broad range of biological systems, together with its label-free operation, relatively high throughput, ability to rank ligands and determine K-d, makes FAC-MS a universal tool enabling convenient and efficient screening in the identification of new potential drug leads. Here we will highlight FAC-MS screening studies and discuss where it can be applied in evaluating multiple protein-binding sites, protein-protein interactions and inactive proteins, and also in determining selectivity.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 50 条
  • [31] HYBRID CHROMATOGRAPHIC METHODOLOGIES FOR DRUG ANALYSIS - GC-MS, LC-MS, MS-MS, AND SUPERCRITICAL FLUID CHROMATOGRAPHY-MS
    GAMES, DE
    CLINICAL CHEMISTRY, 1989, 35 (06) : 1055 - 1056
  • [32] Systematic LC/MS metabolite identification in drug discovery
    Clarke, N
    Rindgen, D
    Korfmacher, W
    Cox, K
    ANALYTICAL CHEMISTRY, 2001, 73 (15) : 430A - 439A
  • [33] Integrating automation and LC/MS for drug discovery bioanalysis
    Rossi, DT
    JOURNAL OF AUTOMATED METHODS & MANAGEMENT IN CHEMISTRY, 2002, 24 (01): : 1 - 7
  • [34] SFC/MS in drug discovery at Pfizer, La Jolla
    Bolaños, B
    Greig, M
    Ventura, M
    Farrell, W
    Aurigemma, CM
    Li, H
    Quenzer, TL
    Tivel, K
    Bylund, JMR
    Tran, P
    Pham, C
    Phillipson, D
    INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, 2004, 238 (02) : 85 - 97
  • [35] Development of a drug discovery pipeline for secondary progressive MS
    Quintana, F. J.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 15 - 15
  • [36] Disability Specific Drug Discovery in MS: Focus on Vision
    Tassoni, Alessia
    Itoh, Yuichiro
    Itoh, Noriko
    Farkhondeh, Vista
    Sofroniew, Michael
    Voskuhl, Rhonda
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 5 - 6
  • [37] Detection of heterogeneous drug-protein binding by frontal analysis and high-performance affinity chromatography
    Tong, Zenghan
    Joseph, K. S.
    Hage, David S.
    JOURNAL OF CHROMATOGRAPHY A, 2011, 1218 (49) : 8915 - 8924
  • [38] LC-MS/MS approach to 'metabonomics' - What can it do for drug discovery/development?
    Shockcor, JP
    Nichols, A
    Antti, H
    Plumb, RS
    Castro-Perez, JM
    Major, H
    Preece, S
    DRUG METABOLISM REVIEWS, 2003, 35 : 1 - 1
  • [39] Antisense oligonucleotides (ASO) quantitation by LC/MS/MS in support of ASO drug discovery and development
    He, L
    Chen, YS
    Zhu, YD
    Mansoori, B
    Duan, L
    Anderson, L
    Shen, H
    Lam, Z
    Chien, B
    Lin, JR
    DRUG METABOLISM REVIEWS, 2003, 35 : 80 - 80
  • [40] Gluten Detection and Speciation by Liquid Chromatography Mass Spectrometry (LC-MS/MS)
    Lock, Stephen
    FOODS, 2014, 3 (01): : 13 - 29